Leading The Way
DEAR FRIENDS,

“Our efforts are clearly paying off, as many concepts we supported in early-stage research are now in phase 2 trials, moving us closer to a cure.”

In 1998, we created the Alzheimer’s Drug Discovery Foundation (ADDF) based on our desire to accelerate drug development for a horrendous disease whose impact was expected to rapidly multiply in coming decades. Over 20 years later, we are proud of the leadership role the ADDF has assumed in the ongoing search for treatments and prevention strategies—and even a cure—for this disruptive and devastating illness.

Our mission has remained the same since our inception: to use a venture philanthropy funding model to push the research “envelope” and support bold, yet sometimes overlooked, efforts. This strategy has enabled us to lead the way toward a diverse range of novel discoveries that have altered the course of Alzheimer’s research. Our efforts are clearly paying off, as many concepts we supported in early-stage research are now in phase 2 trials, moving us closer to a cure.

Through the years, our singular focus on the science needed to conquer Alzheimer’s disease has attracted the collaboration of top scientists. Leading business luminaries, including Bill Gates, Jeff Bezos, and Mackenzie Scott, continue to partner with us as we seek cutting-edge discoveries such as affordable, non-invasive biomarkers that will one day make early Alzheimer’s diagnosis a reality.

We have stepped up efforts to promote thought leadership in the Alzheimer’s arena, and have heightened our support for scientific forums and panels, articles, papers, and other educational efforts, including our Cognitive Vitality website—all designed to keep the public in the Alzheimer’s information loop.

As always, we are grateful for the generosity of our donors, whose help has allowed us to move closer to the answers we are seeking. We are confident that with ongoing support, the ADDF will continue to lead the way toward the discovery of Alzheimer’s treatments.

With sincere thanks,

LEONARD A. LAUDER  
Co-Chairman and Co-Founder

RONALD S. LAUDER  
Co-Chairman and Co-Founder
DEAR FRIENDS,

“ADDF’s recognition of the relationship between aging and Alzheimer’s incidence led the way to broader thinking about the disease.”

This is an exciting time for the Alzheimer’s Drug Discovery Foundation (ADDF). As leaders at the forefront of Alzheimer’s research, we have sought out and supported the work of scientists willing to think big in their quest to find treatments and a cure for Alzheimer’s disease.

For years, the Alzheimer’s research community remained solely focused on misfolded beta amyloid and tau plaques in the brain. But the ADDF’s recognition of the relationship between aging and Alzheimer’s incidence led the way to broader thinking about the disease. It is now commonly believed that Alzheimer’s therapies will likely stem from an enhanced understanding of the effects of aging on the brain.

As you will read in this report, this past year we continued to translate the biology of aging into new treatments, by supporting a variety of drugs aimed at multiple aging malfunctions, including neuroinflammation, vascular problems, epigenetics, synapse loss, and metabolic and mitochondrial dysfunction. Our portfolio is diversified, with equal weight given to novel targets, repurposed drugs, and prevention agents.

While many of our original efforts were aimed at preclinical discovery, we have since pivoted to emphasize clinical development, helping to advance promising trials that are further along the research pipeline.

Our scientific leadership also expands to our ongoing quest—shared with our philanthropic partners—to discover viable Alzheimer’s biomarkers through our Diagnostics Accelerator partnership, as well as our increased support for Alzheimer’s prevention strategies. We have recently intensified our commitment to better understand related dementias by continuing our important collaboration with The Association for Frontotemporal Degeneration (AFTD).

As the focus of research shifts towards more innovative targets for treating Alzheimer’s and related dementias, the ADDF is poised to continue its leadership role in driving exciting scientific discoveries. We are beginning the next decade with the knowledge that each year brings us closer to achieving our mission to conquer Alzheimer’s disease.

With gratitude for your support,

Howard Fillit, MD
Founding Executive Director and Chief Science Officer
By any measure, since our inception in 1998, the Alzheimer’s Drug Discovery Foundation (ADDF) has indisputably played a leadership role in the quest to better understand the mysteries of Alzheimer’s disease. To date, we have supported one of the most comprehensive and diverse portfolios in the field, providing $150 million to fund over 626 programs worldwide to support preclinical, clinical, neuroimaging, CSF tests, and biomarker discovery programs.

Perhaps more than any other year, 2019 illustrated the myriad ways in which we have been at the forefront, leading the way towards an Alzheimer’s cure. The $30 million we invested supported 38 programs in our core discovery areas.

The pages that follow illustrate a year of forward momentum and exciting accomplishments, when the ADDF:

MARKERS OF LEADERSHIP

Spearheading a vision... Charting the course from idea to reality... Inspiring the confidence to motivate others... All are markers of leadership.

Furthered the notion that a diversified research approach—beyond amyloid—will be necessary to identify the Alzheimer’s answers we seek

Continued to marshal the efforts of top scientists to extend the exploration of drugs using “the biology of aging,” or the totality of changes that occur as we age, as a blueprint for discovery

Expanded the ongoing pursuit of viable biomarkers that will eventually ease diagnosis

Forged new partnerships with eminent business leaders, philanthropists, and organizations to collaborate in the battle against Alzheimer’s and related dementias

Leveraged our venture philanthropy fundraising model to achieve ongoing success

Increased support for Alzheimer’s prevention strategies

ALLOW US TO LEAD YOU THROUGH THE JOURNEY THAT WAS

“THE ADDF 2019”
2019 marked both the end of a decade and a pivotal time in Alzheimer’s research. For the better part of the past 30 years, the Alzheimer’s drug discovery world has been laser-focused on trying to understand and manage the abnormal accumulation of plaques and tangles that are hallmarks of the disease and can occur in the brain with advancing age. At the ADDF, we have long-suspected that Alzheimer’s disease is likely the result of multiple aging-related factors. As such, our research platform has supported a diverse drug pipeline that addresses the full range of age-related physiological changes that may contribute to this complex disease.

A multi-target approach to research has been gaining ground in recent years among the larger Alzheimer’s drug development community. According to the ADDF’s Clinical Trials Report released in early 2019, there were 102 potential treatments for Alzheimer’s disease in clinical development at that time—the majority focused on novel, non-amyloid targets such as neuroinflammation, epigenetics, and synapse loss. We are proud to have provided funding for nearly 20% of these clinical stage drugs.

In 2019, we further explored new categories of Alzheimer’s therapies, including repurposed drugs—already FDA-approved for other conditions—and combination therapies that target multiple mechanisms of disease pathogenesis at once to broaden therapeutic attack. And we were gratified to see that many of the ideas we identified and shepherded in early stage research moved on to phase 2 studies.

We placed our bets on potentially breakthrough agents and innovative approaches, several of which reached research milestones in 2019, including:

**THE FIRST NON-ANTI-AMYLOID COMBINATION THERAPY PROGRAM: PEGASUS TRIAL OF AMX0035, FROM AMYLYX PHARMACEUTICALS**

... This two-drug treatment aims to prevent dual aging pathologies, both of which contribute to nerve cell death. Preliminary results are encouraging in patients suffering from ALS, a related neurodegenerative disease. With our support, phase 2 research commenced for its use in Alzheimer’s patients.

**A VACCINE AIMED AT ARRESTING NEUROINFLAMMATION IN THE PROGRESSION OF ALZHEIMER’S DISEASE: PEPINEMAB (VX15/2503) FROM VACCINEX**

... This treatment addresses another age-related physiological change—neuroinflammation. The ADDF provided funds for a phase 2a clinical trial to assess changes in key biomarkers: glucose metabolism in the brain and neuroinflammation.

**A NOVEL MECHANISM TO STOP THE BINDING OF TOXIC PROTEINS THAT BUILD UP IN THE BRAIN AND DAMAGE SYNAPSES: ELAYTA FROM COGNITION THERAPEUTICS, INC.**

... Elayta is being tested in phase 2 clinical studies, supported in part by a grant from the National Institutes of Health (NIH). A critical component of these trials is measuring the drug’s effects on levels of toxic proteins and markers of synaptic damage—one of the primary drivers of Alzheimer’s disease. ADDF funding will allow for the inclusion of these endpoints in the trials and answer important questions about how the drug is working in the target patient population.
"At year-end, the ADDF was proudly supporting the clinical trials of more than 25 drugs that target novel mechanisms of aging, such as neuroinflammation, epigenetics, and synapse loss. Nearly 75% of funded trials were in phase 2."
We are proud that our ongoing support has helped further the innovative work of renowned researchers, among them:

JEFFREY CUMMINGS, MD, ScD, Research Professor of the Department of Brain Health at the University of Nevada, Las Vegas and Director of the Center for Neurodegeneration and Translational Neuroscience at the Cleveland Clinic’s Lou Ruvo Center for Brain Health, who is working to slow Alzheimer’s progression via the repurposing of rasagiline, a drug already approved for Parkinson’s disease. Dr. Cummings reported positive phase 2 findings at our 20th International Conference on Alzheimer’s Drug Discovery and at the 12th Clinical Trials on Alzheimer’s Disease conference. We honored his accomplishments by naming him recipient of our 2019 Melvin R. Goodes Prize for Excellence in Alzheimer’s Drug Discovery.

“Rasagiline is a multifunctional molecule, with a neuroprotective effect and an effect on amyloid. We now think that interfering with multiple Alzheimer’s pathways will be critical to the success of an Alzheimer’s drug. Rather than using a combination of drugs, you can use a single drug that has multiple effects.”

—Jeffrey Cummings, MD, ScD

ROBERTA DIAZ BRINTON, PhD, Director of the Center for Innovation in Brain Science at the University of Arizona and Regents Professor of Pharmacology and Neurology in the College of Medicine—Tucson, who is exploring whether allopregnanolone, a neuroactive metabolite of progesterone, can spur neurogenesis—a promising process that could regenerate brain cells and restore cognitive function in Alzheimer’s patients. The ADDF’s support over the previous 15 years helped lead to a 2019 grant of $37.5 million from the National Institute of Aging (NIA).

“It appears that allopregnanolone is most beneficial in those who carry the risk factor gene for Alzheimer’s disease.”

—Roberta Diaz Brinton, PhD
MICHELA GALLAGHER, PhD, Krieger-Eisenhower Professor of Psychology and Neuroscience, Head of the Neurogenetics and Behavior Center at Johns Hopkins University, and Founder of the therapeutics company AgeneBio, whose work on combating over-activity in the aging brain has garnered long-term support from the ADF as she develops AGB101, a once-a-day investigational medication to treat amnestic mild cognitive impairment (MCI) due to Alzheimer’s disease. A phase 3 trial now aims to determine whether this drug (AGB101), already FDA-approved for treating seizures in epilepsy patients, can halt the progression of brain impairment and prevent dementia.

“If we can prolong the usually decade-long transition from mild cognitive impairment to dementia for five years, we could decrease the number of people with dementia by 50%.”

—Michela Gallagher, PhD

DR. FRANK LONGO, MD, PhD, George E. and Lucy Becker Professor and Chair of the Department of Neurology and Neurological Sciences at Stanford University and Board Chairman and Founder of the biopharmaceutical firm PharmatrophiX. He is working on restoring synaptic activity and lost cognitive function through the use of an agent known as LM11A-31. This potentially revolutionary treatment, now in phase 2a clinical trials, could provide one of the first neuroprotective therapies for Alzheimer’s and other forms of dementia.

“I’m not going to give up on the 50 million people in the world who have a diagnosis of Alzheimer’s. We can create therapies to get synaptic function back at least to a significant extent.”

—Frank Longo, MD, PhD
AREAS OF PREVENTION
We are gaining a wealth of knowledge in the area of prevention to arm clinicians and individuals with better information on reducing risk.

**EFFECT OF EARLY SUPPLEMENTATION WITH HIGH DOSE DHA ON COGNITIVE OUTCOMES IN APOE4 CARRIERS: PreventE4 TRIAL**

... DHA, an omega-3 fatty acid found in fish, is a supplement available at any vitamin or drug store. Hussein Yassine, MD, and his team at the University of Southern California are testing whether a high dose of DHA can prevent cognitive decline in individuals with APOE4, the greatest genetic risk factor for Alzheimer’s disease. In 2019, Dr. Yassine received funding from the NIH to treat 160 participants with DHA to see how much enters the brain. ADDF funding added an additional 160 to the ongoing study, bringing the number of participants to 320, allowing Dr. Yassine and colleagues to see whether DHA preserves memory function and brain structure.

**EFFECTS OF EARLY MENOPAUSAL HORMONE THERAPY ON IMAGING BIOMARKERS OF COGNITIVE HEALTH**

... Kejal Kantarci, MD, MS, of Mayo Clinic will be performing a 12-year follow-up of the Kronos Early Estrogen Prevention Study (KEEPS), a nationwide clinical trial that tested two different menopausal hormone therapies in newly postmenopausal women. This study provides a unique opportunity to clarify the long-term effects of menopausal hormone therapies on cognitive health and Alzheimer’s risk. Add-on funding from the ADDF is being used to support brain imaging of tau, a biological marker of Alzheimer’s disease. Findings from this study will inform whether postmenopausal women should take hormone replacement therapy and which kind may be most protective for brain health.
FORGING NEW ALLIANCES ON THE FRONT LINES OF THE DEMENTIA BATTLE
In order to advance our understanding of Alzheimer’s and develop an effective therapy, we need a simple, non-invasive test to easily and accurately identify patients at the earliest stages of disease.”

—Bill Gates

As part of our Diagnostics Accelerator partnership, the ADDF and The Association for Frontotemporal Degeneration (AFTD) also announced an award to the Bluefield Project to Cure FTD, aimed at discovering biomarkers for the early diagnosis of FTD and predicting who will advance to dementia in coming years.

Through the Treat FTD Fund, we joined forces with the AFTD to support clinical trials, including one conducted by Barbara Borroni, MD, at the University of Brescia in Italy. Her efforts are aimed at exploring the use of repeated sessions of transcranial direct current stimulation (tDCS) to improve cognitive function in patients with FTD, the most common form of dementia for individuals under age 60. Results presented at our 2oth International Conference on Alzheimer’s Drug Discovery held in September provided optimism that this technique could become the first non-pharmacological, non-invasive approach to improving cognition in patients with FTD.
Since our inception, our distinctive approach to funding discovery projects has been based on the concept of venture philanthropy. We use philanthropic capital to make investments in the projects we support and then funnel 100% of the returns back into additional research. Because we are dedicated to finding a cure as opposed to making a profit, we can take risks—leaving no stone unturned in finding innovative ways to defeat this disease and advancing ideas that would otherwise stagnate or disappear. Once the ADDF has effectively “de-risked” these alternative approaches, other investors frequently step in to lend their support. We are proud that our forward-thinking, proactive funding model has helped fill the gap between basic academic research, funded largely by the government, and later-stage clinical trials typically funded by large pharmaceutical companies.

Through the years, we have employed venture philanthropy to support novel ideas from early-stage biopharmas, helping these companies gain credibility.

*An example of success that came to fruition:*

Roughly five years ago, we invested in Rodin Therapeutics to support preclinical development for their novel drug that affects gene expression, strengthens existing synapses, and promotes the creation of new synapses as a treatment for neurodegenerative disorders such as Alzheimer’s. These efforts eventually led to a drug that entered phase 1 research and to the acquisition of Rodin by Alkermes PLC in November 2019—a prime example of how our small early investment helped to lessen risk and propel additional investment in a clinical trial. In turn, financial returns realized by the ADDF’s early backing of Rodin have been re-invested in future research.
1. **ADDF’S PHILANTHROPIC CAPITAL**

   The ADDF invests in projects that are typically deemed “risky” by the Alzheimer’s research community.

2. **ALTERNATE APPROACHES**

   Once these projects have been effectively “de-risked” through the ADDF’s support, other investors frequently step in to lend their support.

3. **ALZHEIMER’S-FOCUSED RESEARCH AND PROJECTS**

   The ADDF takes 100% of the investment returns and invests them in further projects, allowing for additional research.
BRAIN HEALTH AND ALZHEIMER’S PREVENTION: CognitiveVitality.org
In 2019, the ADDF furthered our commitment to providing evidence-based resources on Alzheimer’s prevention by uploading new content to CognitiveVitality.org. This content hub, created in 2014, contains blog posts written by the ADDF’s team of neuroscientists examining issues related to Alzheimer’s prevention and brain health, as well as research reports and ratings evaluating the safety, potential benefit, and available evidence for various vitamins, supplements, foods, and other brain health interventions. Blog topics range from the relationship between sleep and Alzheimer’s to the need to be wary of pseudo medicines promising to improve brain health.

The importance of providing these resources for the public is clear as the audience of CognitiveVitality.org continues to grow, with a total of nearly 1.8 million pageviews in 2019, which more than doubled from 2018.
NEW AND CONTINUING PROGRAMS IN 2019

* Indicates ADDF support of different programs led by the same researcher

**VASCULAR**

Healthy blood flow is essential for providing neurons with sufficient oxygen and vital nutrients. These researchers are targeting vascular damage to improve brain function.

Sandra Black, MD, FRCP(C)
Sunnybrook Research Institute, University of Toronto
Clinical Phase 2
$450,000

Atticus Hainsworth, PhD
St George’s University of London
Clinical Phase 2
$464,992

Ihab Hajjar, MD, MS
Emory University
Clinical Phase 2
$973,777

**SYNAPTIC ACTIVITY & NEUROTRANSMITTERS**

Neurotransmitters carry signals across synapses, which are connections between neurons. These processes are critical for memory and cognition.

Jeffrey Cummings, MD, ScD
Cleveland Clinic Lou Ruvo Center for Brain Health
Clinical Phase 2
$1,150,000

Michela Gallagher, PhD
AgeneBio, Inc
Clinical Phase 3
$150,000

Giacomo Koch, MD, PhD
Santa Lucia Foundation
Clinical Phase 2
$602,800

&
$250,000

Chien-liang Lin, PhD
Ohio State University
IND-Enabling Safety Pharmacology and Toxicology
$795,235

Paul Newhouse*, MD
Vanderbilt University Medical Center
Clinical Phase 1
$1,271,174
&
Clinical Phase 2
$539,799

Ana Pereira, MD
Icahn School of Medicine at Mount Sinai
Clinical Phase 2
$106,000

Dianne Perez, PhD
Cleveland Clinic Foundation
Lead Optimization/Medicinal Chemistry
$381,340

Jerri Rook, PhD
Vanderbilt Center of Neuroscience Drug Discovery
Preclinical Testing
$150,000

Sharon Rosenzweig-Lipson, PhD
AgeneBio, Inc
Preclinical Testing
$499,704

**INFLAMMATION**

These scientists are investigating drugs that protect against inflammation in the brain caused by disease and injury, which can accelerate or trigger Alzheimer’s.

Kevin Hodgetts, PhD
Laboratory for Drug Discovery in Neurodegeneration (LDDN)
Preclinical Testing
$600,000

Masahi Kitazawa, PhD
University of California, Irvine
Preclinical Testing
$328,000

Krista Lanctôt, PhD
Sunnybrook Research Institute
Clinical Phase 2
$1,396,867

Alexandros Makriyannis, PhD
Northeastern University
Lead Optimization/Medicinal Chemistry
$230,000

John Olichney, MD
University of California Davis School of Medicine
Drug Manufacture - Synthesis and Formulation
$1,034,991
Michael Parker, DPhil, FAA, FAHMS
St. Vincent’s Institute of Medical Research
Hit Identification/Secondary Screening
$345,754

Erik Roberson, MD, PhD
University of Alabama at Birmingham
Target Discovery
$600,000

Marwan Sabbagh, MD
Cleveland Clinic Lou Ruvo Center for Brain Health
Clinical Phase 1
$1,396,475

Eric Siemers, MD
Vaccinex Inc.
Clinical Phase 1
$2,392,766

Edward Spack, PhD
MedaRed, Inc.
ADME and PK
$3,000,000

Linda Van Eldik, PhD
University of Kentucky Research Foundation
Clinical Phase 1
$1,434,160

Manfred Windisch, PhD
Neurokinine Therapeutics
Clinical Phase 1
$1,688,985

These investments include comparative effectiveness and clinical research of prevention strategies to lower the risks of developing dementia.

Joel Dudley, PhD
Icahn School of Medicine at Mount Sinai
Epidemiology
$100,000

Sharon Inouye, MD, MPH
Hebrew SeniorLife
Other
$1,069,609

Kejal Kantarci, MD, MS
Mayo Clinic Rochester
Epidemiology
$66,094

Hiroaki Sato, MD, PhD
Research Institute of the McGill University Health Centre
$782,461

Phillip Tully, PhD, MPsych, BHSc
University of Adelaide
Epidemiology
$99,363

Bruno Vellas, MD
Toulouse Centre of Excellence in Neurodegeneration
University Hospital Toulouse
Clinical Phase 2
$300,000

George Vradenburg
UsAgainstAlzheimer’s Network
$1,000,000

Kristine Yaffe, MD
University of California San Francisco
Epidemiology
$100,000

Hussein Yassine, MD
University of Southern California
Clinical Phase 2
$1,500,000

As Alzheimer’s progresses, neurons (or nerve cells) lose their connections and begin to die, causing the loss of memory and other cognitive functions. These scientists are exploring “neuroprotective” treatment strategies to shield neurons from damage and death.

Roberta Diaz Brinton, PhD
University of Arizona
Clinical Phase 2
$600,000

Susan Catalano, PhD
Cognition Therapeutics, Inc.
Clinical Phase 2
$2,000,000

Thomas Franke, MD, PhD
Icahn School of Medicine at Mount Sinai
Lead Optimization/Medicinal Chemistry
$233,505

Justin Ichida, PhD
University of Southern California
Preclinical Testing
$150,000

Leen Kawas, PhD
Athira Pharma, Inc.
Clinical Phase 1
$1,397,630
These scientists are pursuing approaches to prevent or clear the accumulation of misfolded proteins, which causes damage to brain cells.

Travis Dunckley, PhD  
Arizona State University Foundation  
Preclinical Testing  
$251,154

Steven Finkbeiner, MD, PhD  
The J. David Gladstone Institutes  
Assay Development/High Throughput Screening  
$150,000

Edward Huey, MD  
Trustees of Columbia University in the City of New York  
Clinical Phase 2  
$532,335

Luana Fioriti, PhD  
Plico Biotech, Inc  
Preclinical Testing  
$148,000

Douglas Galasko, MD  
University of California, San Diego  
Clinical Phase 2  
$500,000

Sam Gandy, MD, PhD  
Icahn School of Medicine at Mount Sinai  
$187,069

John Gerdes, PhD  
RIO Pharmaceuticals, Inc.  
$308,869

Frank Longo, MD, PhD  
PharmatrophiX  
Clinical Phase 2  
$500,000

William Ray, PhD  
The Neurodegeneration Consortium, MD Anderson  
Lead Optimization/Medicinal Chemistry  
$338,620

Grace Stutzmann, PhD  
NeuroLucent, Inc  
Lead Optimization/Medicinal Chemistry  
$338,985  
&  
$257,942

Ronald van der Geest, PhD  
Treeway B.V.  
Clinical Phase 2  
$2,994,123

John “Kent” Werner, MD, PhD  
Cogentis Therapeutics  
ADME and PK  
$188,193

Sung Ok Yoon, PhD  
Ohio State University  
Preclinical Testing  
$473,997

Yan Zhang, PhD  
The University of Texas at Austin  
Lead Optimization/Medicinal Chemistry  
$350,000

Janice Kranz, PhD  
Eikonizo Therapeutics, Inc.  
Clinical Phase 0  
$1,000,051

Thomas Kukar, PhD  
Emory University  
Preclinical Testing  
$150,000

Raymond Turner, MD, PhD  
Georgetown University  
Clinical Phase 2  
$2,104,000

Yuval Dor, PhD  
Hebrew University, Faculty of Medicine  
$500,000

Saliha Moussaoui, PhD  
Amoneta Diagnostics  
$2,000,000

Biomarkers are tools used to diagnose a disease and assess its progression and response to treatment. These researchers aim to develop more accurate biomarkers for clinical trials.

Kaj Blennow, MD, PhD  
University of Gothenburg  
$500,000

Franc Llorens, PhD  
CIBERNED-CNB-CSIC  
$228,000

Val Lowe, MD  
Mayo Clinic Rochester  
$347,582

Tom MacGillivray, BSc, MSc, PhD  
University of Edinburgh  
$488,997

John “Kent” Werner, MD, PhD  
Cogentis Therapeutics  
ADME and PK  
$188,193

Raymond Turner, MD, PhD  
Georgetown University  
Clinical Phase 2  
$2,104,000

Grace Stutzmann, PhD  
NeuroLucent, Inc  
Lead Optimization/Medicinal Chemistry  
$338,985  
&  
$257,942

Laura Ibanez, PhD  
Washington University in St. Louis  
$281,370

Clifford Jack, MD  
Mayo Clinic Rochester  
$499,143

Chunlei Liu, PhD  
Regents of the University of California at Berkeley  
Target Validation  
$500,000

Franc Llorens, PhD  
CIBERNED-CNB-CSIC  
$228,000

Val Lowe, MD  
Mayo Clinic Rochester  
$347,582

Tom MacGillivray, BSc, MSc, PhD  
University of Edinburgh  
$488,997

Saliha Moussaoui, PhD  
Amoneta Diagnostics  
$2,000,000
As we age, mitochondria, the energy centers of our cells, can become impaired. These researchers are developing drugs targeting this dysfunction.

MITOCHONDRIA & METABOLIC FUNCTION

GENETICS & EPIGENETICS

These therapies target genetic risk factors like APOE and epigenetics, which regulate how much genes are expressed.

As we age, mitochondria, the energy centers of our cells, can become impaired. These researchers are developing drugs targeting this dysfunction.

MITOCHONDRIA & METABOLIC FUNCTION

GENETICS & EPIGENETICS

These therapies target genetic risk factors like APOE and epigenetics, which regulate how much genes are expressed.

As we age, mitochondria, the energy centers of our cells, can become impaired. These researchers are developing drugs targeting this dysfunction.

MITOCHONDRIA & METABOLIC FUNCTION

GENETICS & EPIGENETICS

These therapies target genetic risk factors like APOE and epigenetics, which regulate how much genes are expressed.

As we age, mitochondria, the energy centers of our cells, can become impaired. These researchers are developing drugs targeting this dysfunction.

MITOCHONDRIA & METABOLIC FUNCTION

GENETICS & EPIGENETICS

These therapies target genetic risk factors like APOE and epigenetics, which regulate how much genes are expressed.
SALUTING OUR LEADERS AND SUPPORTERS

In 2019, we honored several exemplary ADDF supporters for their dedication, leadership, and commitment to advancing our mission.

PAMELA J. NEWMAN
In recognition of her dedication, we honored Pamela J. Newman with the Charles Evans Award at the Tenth Annual “Hope on the Horizon” Fall Symposium & Luncheon in New York City.

MARCIA GAY HARDEN
Actress, author, and advocate Marcia Gay Harden was honored at the Second Annual Hope on the Horizon Palm Beach Luncheon for her inspiration and advocacy in support of Alzheimer’s research.

TJ OSIE
Washington Capitals hockey player and 2018 Stanley Cup winner TJ Oshie was honored at the Ninth Annual Great Ladies Luncheon & Fashion Show for his commitment to advancing awareness of Alzheimer’s disease since his father was diagnosed in 2012.

DR. MICHELA GALLAGHER
Dr. Michela Gallagher, Founder and CEO of AgeneBio, Inc. and professor at Johns Hopkins University, was honored at the Ninth Annual Great Ladies Luncheon with the inaugural Estelle Gelman Award for her groundbreaking research.

DxA
As the ADDF celebrated the one-year anniversary of our new research initiative, the Diagnostics Accelerator (DxA), we recognized prominent philanthropists for funding this program: Bill Gates, Jeff Bezos, MacKenzie Scott, the Dolby family, the Charles and Helen Schwab Foundation, The Association for Frontotemporal Degeneration, and others.

DR. JEFFREY CUMMINGS
Renowned Alzheimer’s researcher and leader in clinical trials Dr. Jeffrey Cummings was named the recipient of the 2019 Melvin R. Goodes Prize for Excellence in Alzheimer’s Drug Discovery.

< Mark Roihmays, Dr. Niranjan Bose, Leonard A. Lauder, Ronald S. Lauder at the Connoisseur’s Dinner
2019 EVENT HIGHLIGHTS

Second Annual
HOPE ON THE HORIZON
PALM BEACH LUNCHEON
March 4, 2019 | Palm Beach
The event honored Marcia Gay Harden, Academy and Tony Award winner, author, and activist, for her efforts to raise Alzheimer’s awareness.

Second Annual
MEMORIES MATTER
April 9, 2019 | New York City
Hosted by Weather Anchor for NBC4 New York Dave Price, the event featured Michelle Florin, who shared a heartfelt tribute to her mother, and country singer Ashley Campbell.

Heidi and Tom McWilliams
Judy Glickman Lauder, Leonard A. Lauder
Jan Willinger, Marcia Gay Harden, Leonard A. Lauder, Nancy Goodes
Bonnie Lautenberg, Nancy Goodes
Michelle Florin
Dr. Howard Fillit, Leonard A. Lauder, Mark Rothmayer
Ronald Dickerman, Wendy Wilshin, Stephanie Ginsberg, Ian Ginsberg
Anne Diamond, Carla Karen, Cindy Edelman, Amelia Paston, Wendy Wilshin, Stephanie Ginsberg, Karen Spector
Ninth Annual
GREAT LADIES LUNCHEON AND FASHION SHOW
May 1, 2019 | Washington, DC
Hosted by sports broadcaster Lindsay Czarniak, the event honored TJ Oshie of the Washington Capitals and Michela Gallagher, PhD, Founder and CEO of AgeneBio, Inc., and featured the Carolina Herrera Spring and Fall 2019 Collections.

Thirteenth Annual
CONNOISSEUR’S DINNER
May 30, 2019 | New York City
The gala celebrated the one-year anniversary of Diagnostics Accelerator and recognized the program’s funding partners Bill Gates, Leonard A. Lauder, the Dolby family, the Charles and Helen Schwab Foundation, Jeff Bezos, MacKenzie Scott, and others.
Fifth Annual
MELVIN R. GOODES PRIZE
Sept 13, 2019 | New York City
We were proud to present the 2019 Melvin R. Goodes Prize to Dr. Jeffrey Cummings.

Tenth Annual
FALL SYMPOSIUM AND LUNCHEON
Nov 1, 2019 | New York City
Hosted by Paula Zahn, this year’s event honored Pamela J. Newman, CEO of PNJ Strategies with the Charles Evans Award.

2019 TCS NEW YORK CITY MARATHON
Nov 3, 2019 | New York City
Sarah Abell, a member of the ADDF’s 2019 NYC Marathon team.
OUR SUPPORTERS

We are deeply grateful to all those who supported our work in 2019. Your generosity gives us hope for a future without Alzheimer’s disease.

$1,000,000 AND ABOVE
Anonymous
Association for Frontotemporal Degeneration
Jeffrey Bezos
Dagmar Dolby Fund
Foundation for a Better World
Gates Ventures
Judy and Leonard A. Lauder
MacKenzie Scott

$500,000–$999,999
Charles and Helen Schwab Foundation
Edward Goodnow
Jo Carole and Ronald S. Lauder

$250,000–$499,999
Anonymous
Renée and Robert Belfer
Natasha and David Dolby
Kate and John Krebsbiel
The Lauder Foundation

$100,000–$249,999
Davis Polk & Wardwell, LLP
The Eranda Rothschild Foundation
Caroline Fitzgibbons and Thomas Smith
Roslyn Goldstein
Nancy and Melvin R. Goodes
Janet Traeger Salz Charitable Trust
Frances and Nathan Kirsh
Lattner Family Foundation
Laura and Gary Lauder
Susan and Thomas Lowder
Melvin R. Goodes Family Foundation
Catherine and Michael Podell
Ray and Kay Eckstein Charitable Trust
Peggy Rice
Samuel I. Newhouse Foundation, Inc.
Lizabeh Furman Sandler and Randal Sandler Shear Family Foundation
Tuchman Family Foundation
Carolyn and Malcolm Wiener

$50,000–$99,999
A.P. Kirby, Jr. Foundation, Inc.
William Ackman
Carol and Jack Aten
The Calvin Klein Family Foundation
Caryn J. Clayman
Joyce Cowin
The Estée Lauder Companies, Inc.
The Krebsbiel Family Foundation
Estate of Evelyn H. Lauder
William P. Lauder
Laurence C. Leeds, Jr.
The Lefkofsky Family Foundation
Elise and Marc Lefkowitz
Melvin and Estelle Gelman Foundation
Julie Chrystyn Opperman
Sharon and Robert Prince
Anne and J. Christopher Reyes
Nathan E. Saint-Amand

$25,000–$49,999
A.P. Kirby, Jr. Foundation, Inc.
William Ackman
Carol and Jack Aten
The Calvin Klein Family Foundation
Caryn J. Clayman
Joyce Cowin
The Estée Lauder Companies, Inc.
The Krebsbiel Family Foundation
Estate of Evelyn H. Lauder
William P. Lauder
Laurence C. Leeds, Jr.
The Lefkofsky Family Foundation
Elise and Marc Lefkowitz
Melvin and Estelle Gelman Foundation
Julie Chrystyn Opperman
Sharon and Robert Prince
Anne and J. Christopher Reyes
Nathan E. Saint-Amand
Thomas Scanlan
Iris Smith
Mia and Sheldon Solow
Steelfab, Inc.
Thomas W. Smith Foundation
Barbara and Donald Tober
Sandra and Bruce Tully
George A. Vradenburg III
Carol and Michael Weisman
Jan Willinger and Robert Spiegel
Paula Zahn and Paul Fribourg

$10,000–$24,999
Anonymous (2)
Daniel Abraham
Pennie and Gary Abramson
Steve Acunto
Aon Foundation
Shelley and Robert Banks
Terry Boyer
Bramshill Investments LLC
Bettina and Donald Bryant
James Buller
Linda and Arthur Carter
Kristin and John Cecchi
Clifford Chance US LLP
Marcella and Neil Cohen
Michael T. Cohen
Michelle Romanoff Cohen
Colliers International
Gina and Kurt Conti
Carole Cooper and Richard Leibner
Corvest Capital Partners LLC
Nancy Corzine
Crown Equipment
Barbaralee Diamonstein-Spielvogel and Carl Spielvogel
Janet and James Dicke
Ehrenkranz Partners
Betty and David Farrell
Mary C. Farrell
Jerald D. Fessenden
Constance F. Fischer
Claire Foerster and Daniel S. Bernstein
Mary Ann Fribourg
Fried, Frank, Harris, Shriver & Jacobson LLP
Jeffrey Garibaldi
Philip and Julie Geier
Irwin Greenbaum
Audrey and Martin Gruss
Charlene Haroche
Dena Henry
Susan and Roger Hertog
Marlene Hess and James Zirin
Hess Philanthropic Fund
Paul Hilal
Shelley and Allan Holt
Hues for You LLC
Inoac Packaging Group, Inc.
John E. and Sue M. Jackson Charitable Trust
Kiera and Christopher Johnson
Katy Kamen
Cherry and Howard Kaneff
Ron Kaufman
Vicki and Christopher Kellogg
Nancy Kestenbaum and David Klafter
David H. Komansky
Dana and Michael Landow
Judy Lauder
Sheri and Seth Leist
Linda and Steven Levy
Serena and John Liew
Madison International Realty
Roni and Charles McGuffog
Julie Medler
Elaine and William Miller
MorseLife Health System, Inc.
Jennifer Myerberg
Pamela J. Newman
Glenn Nussdorff
Mrs. Michael O’Hare
The Parsons Family Foundation
Nathan Perlmutter
Pfizer Inc.
The Polis-Schutz Family Foundation
Phebe Farrow Port and Thomas David Port
Porter Family Charitable Foundation, Inc.
Thomas C. Quick
Coby Rapaport
Lori and John Reinsberg
Denise Rich
Sharon and Daniel Roitman
Patricia Sagon
Laura Landro and Richard Salomon
June and Paul Schorr
Trish and Steven Shapiro
Donald Sherrill
Glenn Sherrill, Jr.
Klara and Larry Silverstein
Jill and Sanford Sirulnick
Sharon and Cary Stamp
The Starr Foundation
Cindy and Laurence Tell
Ann and Andrew Tisch
Tishman Speyer Properties LP
Pamela D. Wall
Lorraine and Christopher Wallace
Lulu and Anthony Wang
Sandra and Stanford Warshawsky
Cathy Merrill Williams

$5,000–$9,999
Anonymous
Matthew Abramo
Barbara and Philip Altheim
Peter Banks
Ruth Baum
Lisa and Clifford Beek
Robert Bennett
The Berro Family Foundation, Inc.
Myra and Charles Biblowit
Mark Bilski
Faith Bobrow
Merilee and Roy Bostock
Evelyn T. Brandt
Lynda and F. Davis Camalier
Annette and Charles Cangro
Cantor Fitzgerald Relief Fund
Marianne and John Castle
Anla Cheng
Jeanne Coleman
Continental Casualty Company
Ellen Davin
Stephanie Diamond
Amy DiGeso and Paul Rakowski
Douglas DiPasquale
Dorothy G Bender Foundation
Eckert Seamans Cherin & Mellott LLC
Cindy and Glen Edelman
Ernst & Young LLP
First Republic Bank
Michelle Florin
Deborah Forrest
The Frances Alexander Foundation
Mary-Ann and Fabrizio Freda
Barbara and Richard Furman
Julie Garcia
Michael Gargiulo
GCP Capital Group LLC
David Gerson
Amy Gips
Beth and James Glassman
Carol and Henry Goldberg
Phyllis E. Grann
Janet and Allan Green
Laurie and Philip Gross
Susan Gutfreund
The Hartford
Michael Hoffman
Joanna Horgan
Jane Hertzmark Hudis and Clifford Hudis
Lynette and Richard Jaffe
Amy and Scott Jaffe
JJP Ventures LLC
John L. & Sue Ann Weinberg Foundation
Daniel Kaner
Kevin Kelley
Eleonora R. Kennedy
Brooks Kenny
Howard Kessler
Elizabeth Ketels
Sandra R. Killion
Eileen and John Kim
Stacie Kiratsous
George Klett
Paulette Koch
Diana Kogan and Israel Kogan, MD
Deborah and Peter Krulewitch
Raymond Learsy

Anne Marie Lebel
Lynn M. Leonsis
Ellen Levy
The Luminescence Foundation
Marcy Maguire
Alice B. Mahoney
Marlene Malek
The Marc Haas Foundation
Pamela and Tony Marquez
Lisa Mathers
Matrix Private Capital
May and Samuel Rudin Family Foundation
Taylor McCall-Mazza
Justin G. Meltzer
Sandy and Edward Meyer
Sara Moss and Michael Gould
Sarah and Baillieu Myer
Istvan Nadas
Northern Trust
Melanie and Lawrence Nussdorf
Tracy and Bruce Ochsman
Lauren and Timothy Oshie
Jill Podell
R-T Specialty LLC
Rakson Restaurants LLC
Jennifer Redmond
Donna and Charles Reilly
The Richard Foundation
Lisa Ritter-Kahn
Sheila J. Robbins
Michelle and Michael Roberts
Lita Rosenberg
Greg Rosica
Janet C. Ross
Royal Abstract
Sacks & Sacks LLP

Stacy and Kenneth Samet
Gillian Sandler
Benjamin Schall
Jane Scheinfeld
Joan and George Schiele
Hadley and John Scully
Seritage KMT Finance LLC
Stuart Sherrill
Signature Bank
Silvestri Family Foundation
Karen and Spencer Smul
South Dakota Trust Co.
Karen and Marc Spector
Garen Staglin
Debbie and Craig Stapleton
The Starker Family Foundation
Gerald Swartz
Julie and Marc Tell
Laurie Tisch
Mary and Kenneth Walker
Sara and John Walsh
Yan Wang
Ellen and David Wasserman
Daniel Watterson
Rosemary Fine Weaver
Janice Worth
Ann Zimmerli-Haskel and James Haskel
LEADERSHIP

BOARD OF GOVERNORS

The Board of Governors is the principal board of the Corporation with all legal power and authority to manage, oversee, and make decisions regarding the ADDF’s programs and activities. Board members includes leaders from government, industry, and the research community who serve as ambassadors for the ADDF and provide strategic oversight and counsel.

All members as of December 31, 2019.

ADDF HONORARY GOVERNORS
Justice Sandra Day O’Connor
(Retired) Associate Justice, US Supreme Court

Melvin R. Goodes
Former Chairman and CEO, Warner-Lambert

Sally Susman
Executive Vice President, Policy, External Affairs and Communications, Pfizer Inc.

CO-CHAIRMEN
Leonard A. Lauder
Chairman Emeritus, The Estée Lauder Companies, Inc.

Ronald S. Lauder
Chairman, Clinique Laboratories, LLC

VICE CHAIRMAN
Randal Sandler
Director of Client Services and Marketing, Bridgewater Associates

EX OFFICIO
Howard Fillit, MD
Founding Executive Director and Chief Science Officer, The Alzheimer’s Drug Discovery Foundation

TREASURER
Kevin Dieterich
Vice President, Executive Financial Management, The Estée Lauder Companies Inc.

ASSISTANT TREASURER AND SECRETARY
Lisa Somar
Vice President, Executive Financial Management, The Estée Lauder Companies Inc.

GOVERNORS
Robert Belfer
Chairman, Belfer Management

Roberta Diaz Brinton, PhD
Director, UA Center for Innovation in Brain Science at the University of Arizona Health Sciences

Nancy Corzine
President and CEO, Nancy Corzine, Inc.

Lanny Edelsohn
Director, Christiana Care Health Systems, Inc.

Nancy Goodes
Former Executive, Nazareth-Century Mills; Secretary, Melvin R. Goodes Family Foundation, Inc.

Gary M. Lauder
Managing Director, Lauder Partners LLC

Laurence C. Leeds, Jr.
Chairman, Buckingham Capital Management, Inc.

Bruce McEwen, PhD
Alfred E. Mirsky Professor, The Rockefeller University

Thomas McWilliams
Managing Partner, Court Square Capital Partners

Richard Mohs, PhD
Chief Science Officer Global Alzheimer’s Platform Foundation Vice President for Neuroscience Early Clinical Development and Distinguished Research Fellow, Eli Lilly & Company

Steven Paul, MD
CEO, Karuna Therapeutics

Bonnie Pfeifer Evans
Senior Sales Associate, Corcoran Group Real Estate; Co-Trustee, The Charles Evans Foundation

Alice Shure
Founder and Producer, AMICI Productions LLC; Co-Trustee, The Charles Evans Foundation

David R. Weinreb
Chief Executive Officer, Weinreb Ventures

Paula Zahn
Host and Executive Producer, Discovery ID’s “On the Case with Paula Zahn,” and WNET’s “NYC Arts”
LEADERSHIP

BOARD OF OVERSEERS

The Board of Overseers is an advisory body committed to providing counsel and support to the ADDF Board of Governors and staff. Overseers lend their expertise to advance the ADDF’s mission to accelerate the discovery of drugs to prevent, treat, and cure Alzheimer’s disease. Overseers are appointed by, and serve at the pleasure of, the Board of Governors.

All members as of December 31, 2019.

CHAIR
Sharon Sager, CIMA
Managing Director and Private Wealth Advisor, UBS Private Wealth Management

Carol Boulanger
Partner, Pillsbury, Winthrop, Shaw, and Pittman, LLP

Phil Lovett
Founding Partner, Millennium Partners

Charles Cangro
Principal, Personal Financial Services, Ernst & Young (retired)

Julie Medler
Managing Director, Golden Seeds

Mitchell Eichen, JD, LLM
Founder and Chief Executive Officer, Acertus Capital Management (retired) Founder and Chief Executive Officer, The MDE Group (retired)

Justin Meltzer
Real Estate Operations, DLP Piper LLC

Stephanie Ginsberg
Volunteer, Philanthropist, Founder, BCRF Pink Promises Benefit

Pamela Newman, PhD
President and Chief Executive Officer, PJN Strategies

Allan M. Green, MD, PhD, JD
Allan M. Green Esq., LLC

Phebe Farrow Port
Senior Vice President, Global Management Strategies and Chief of Staff to the CEO and President, Executive Management Initiatives, The Estée Lauder Companies, Inc.

John H. Scully, CIMA
Senior Managing Director, Head of Private Wealth Advisory, Nuveen Investments

Christopher Johnson
President, Rackson Corporation

Thomas Scanlan
Consultant, Spencer Stuart

Mitchell Kanef
Chairman & Chief Executive Officer, Arkay Packaging

Stephen Toma
Managing Director, VJMS, LLC

Bonnie Englebardt Lautenberg
Bonnie Lautenberg Designs

Wendy Wilshin
Founder and Principal, WLW Designs

Elise Gelman Lefkowitz
Philanthropist
**2019 FINANCIAL OVERVIEW**

*Full audited 2019 financials available by request*

---

**STATEMENT OF FINANCIAL POSITION**

<table>
<thead>
<tr>
<th>ASSETS</th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cash &amp; cash equivalents</td>
<td>$31,201,758</td>
<td>6,688,572</td>
</tr>
<tr>
<td>Investments, at fair value</td>
<td>43,655,426</td>
<td>47,708,468</td>
</tr>
<tr>
<td>Contributions receivable</td>
<td>22,155,205</td>
<td>35,523,444</td>
</tr>
<tr>
<td>Other assets</td>
<td>163,175</td>
<td>117,739</td>
</tr>
<tr>
<td><strong>Total Assets</strong></td>
<td>$97,175,564</td>
<td>90,038,223</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>LIABILITIES &amp; NET ASSETS</th>
</tr>
</thead>
<tbody>
<tr>
<td>Accounts payable &amp; accrued liabilities</td>
</tr>
<tr>
<td>Grants payable</td>
</tr>
<tr>
<td>Due to Institute for the Study of Aging, Inc</td>
</tr>
<tr>
<td>Deferred revenue</td>
</tr>
<tr>
<td><strong>Total liabilities</strong></td>
</tr>
<tr>
<td><strong>Net Assets</strong></td>
</tr>
<tr>
<td>Without donor restrictions</td>
</tr>
<tr>
<td>With donor restrictions</td>
</tr>
<tr>
<td><strong>Total net assets</strong></td>
</tr>
</tbody>
</table>

**STATEMENT OF ACTIVITIES**

<table>
<thead>
<tr>
<th>CHANGE IN NET ASSETS</th>
<th>2019</th>
<th>2018</th>
</tr>
</thead>
<tbody>
<tr>
<td>Support &amp; Revenues</td>
<td></td>
<td></td>
</tr>
<tr>
<td>Without Donor</td>
<td></td>
<td></td>
</tr>
<tr>
<td>With Donor</td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Support:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contributions &amp; grants</td>
<td>$8,990,901</td>
<td>6,512,230</td>
</tr>
<tr>
<td>Proceeds from special events, net of direct expenses</td>
<td>3,944,614</td>
<td>3,944,614</td>
</tr>
<tr>
<td>Net assets released from restrictions</td>
<td>13,568,366</td>
<td>(13,568,366)</td>
</tr>
<tr>
<td><strong>Revenues:</strong></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Grant returns</td>
<td>2,281,823</td>
<td>(39,722)</td>
</tr>
<tr>
<td>Conference registration fees &amp; other income</td>
<td>74,504</td>
<td>-</td>
</tr>
<tr>
<td>Investment Income</td>
<td>948,041</td>
<td>-</td>
</tr>
<tr>
<td><strong>Total support &amp; revenues</strong></td>
<td>33,825,244</td>
<td>(7,095,858)</td>
</tr>
</tbody>
</table>

| Expenses              |      |      |
| Program services:     |      |      |
| Grants                | 30,307,505 | - | 30,307,505 | 18,468,664 |
| Unexecuted prior year grants | - | - | - | (3,824,811) |
| Other                 | 3,211,623   | - | 3,211,623 | 2,445,626 |
| **Total program services** | 33,519,128 | - | 33,519,128 | 17,089,479 |
| Support services:     |      |      |
| Fund raising          | 1,721,880   | - | 1,721,880 | 1,817,730 |
| Management & general  | 1,205,291   | - | 1,205,291 | 949,103 |
| Total supporting services | 2,927,171 | - | 2,927,171 | 2,766,833 |
| **Total expenses**    | 36,446,299  | - | 36,446,299 | 19,856,312 |
| Change in net assets  | (2,621,055) | (7,095,858) | (9,716,913) | 39,626,554 |
| Net assets, beginning of year | 24,729,290 | 35,204,591 | 59,933,881 | 20,307,327 |

---

*2019 FINANCIAL OVERVIEW*

*Full audited 2019 financials available by request*
All fundraising and management expenses are underwritten by our founders, so your entire donation funds the most innovative drug research around the world.

100% of Your Donation Funds Science

We’re proud to hold GuideStar’s highest charity rating.
Founded in 1998 by Leonard A. Lauder and Ronald S. Lauder, the Alzheimer's Drug Discovery Foundation (ADDF) is the only philanthropy solely focused on accelerating the development of drugs to prevent and treat Alzheimer's disease. Its venture philanthropy approach and scientific expertise allows the ADDF to support the most promising ideas around the world. And 100% of your donation funds drug research programs.

To learn more, visit AlzDiscovery.org.